Pharmafile Logo
Pharmafocus logo
Advanced Search

multiple myeloma

Showing 6 posts of 81 posts found.

Takeda oncology

Takeda cancer drug gets EMA boost

July 29, 2015
Research and Development, Sales and Marketing Takeda, ixazomib, multiple myeloma

The EMA has granted Takeda an accelerated assessment for its multiple myeloma drug, ixazomib. The Agency’s Committee for Medicinal Products …

News
celgene_1_02_1

NICE won’t back Revlimid in new setting

July 31, 2014
Medical Communications, Sales and Marketing Celgene, NICE, Revlimid, Thalidomide, multiple myeloma

NICE has once again said it does not think that Celgene’s rare cancer drug Revlimid should be used on the …

News

J&J buys into Genmab cancer drug

August 31, 2012
Sales and Marketing Cancer, Genmab, Janssen Cilag, Janssen-Cilag, Johnson & Johnson, multiple myeloma

Danish biotech company Genmab has sold the worldwide rights for one of its cancer drugs to Johnson & Johnson-owned Janssen …

News

NICE backs Celgene’s thalidomide and Janssen’s Velcade

June 21, 2011
Sales and Marketing NICE, Thalidomide, Velcade, multiple myeloma

Celgene’s thalidomide and Janssen-Cilag’s Velcade have been given the thumbs up by NICE as a treatment for a cancer that …

News
GSK's UK headquarters

End of the line for GSK’s resveratrol

January 14, 2011
Research and Development GSK, GlaxoSmithKline, SRT2104, SRT2379, SRT501, Sirtris, multiple myeloma, resveratrol

GlaxoSmithKline is halting all work on resveratrol, a compound found in red wine and thought to have life extending properties. …

News
Velcade

Janssen to appeal against Velcade decision

August 26, 2010
Medical Communications, Sales and Marketing NICE, Thalidomide, Velcade, multiple myeloma

Celgene’s Thalidomide has been recommended by NICE for multiple myeloma ahead of Janssen-Cilag’s Velcade. A final appraisal determination says that …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026